News
OGEN
7.14
+5.12%
0.35
BRIEF-Oragenics Regains Compliance With NYSE American
Reuters · 1d ago
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday
Benzinga · 01/23 16:36
Oragenics Files $40 Million Mixed Shelf
Oragenics Files $40 Million Mixed Shelf
MT Newswires · 01/17 05:38
BRIEF-Oragenics Inc Files For Mixed Shelf Of Up To $40 Million
Reuters · 01/13 22:42
Oragenics's Return On Capital Employed Insights
Benzinga · 12/27/2022 14:49
Sector Update: Healthcare Stocks Narrowly Rise Premarket Tuesday
Sector Update: Healthcare Stocks Narrowly Rise Premarket Tuesday
MT Newswires · 12/27/2022 09:16
Metacrine, Equillium And 3 Stocks To Watch Heading Into Tuesday
Benzinga · 12/27/2022 09:12
Oragenics Board OKs 1-for-60 Reverse Stock Split; Shares Down Pre-Bell
Oragenics Board OKs 1-for-60 Reverse Stock Split; Shares Down Pre-Bell
MT Newswires · 12/27/2022 04:44
BRIEF-Oragenics Discloses One-For-Sixty Reverse Stock Split
Reuters · 12/23/2022 21:12
Oragenics Discloses 1-For-60 Reverse Stock Split
Benzinga · 12/23/2022 21:06
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session
Benzinga · 12/22/2022 18:13
Oragenics Highlights Encouraging Toxicology Data From Intranasal COVID Vaccine Candidate
Benzinga · 12/22/2022 17:12
BRIEF-Oragenics Reports Favorable Toxicology Results For Its COVID-19 Intranasal Vaccine Candidate
Reuters · 12/22/2022 12:34
Oragenics Reports Toxicology Results For Its COVID-19 Intranasal Vaccine Candidate; Says No Toxicity Found In NT-CoV2-1
Benzinga · 12/22/2022 12:31
Oragenics Says Study of Intranasal COVID-19 Vaccine Candidate Shows No Toxicity Signals; Shares Jump
Oragenics Says Study of Intranasal COVID-19 Vaccine Candidate Shows No Toxicity Signals; Shares Jump
MT Newswires · 12/22/2022 08:45
Oragenics Gets Noncompliance Notice From NYSE American
Oragenics Gets Noncompliance Notice From NYSE American
MT Newswires · 12/21/2022 04:34
BRIEF-Oragenics Inc Receives NYSE American Notice
Reuters · 12/20/2022 22:24
December 19, 2022, Oragenics Received Notice From The NYSE American Stating That The Company Is Not In Compliance With The Continued Listing Standards
Benzinga · 12/20/2022 21:39
BRIEF-Oragenics Announces New Chair
Reuters · 12/19/2022 21:39
Oragenics, Inc. Announces New Chairman Of The Board Of Directors Succeeding Dr. Frederick W. Telling
Benzinga · 12/19/2022 21:35
More
Webull provides a variety of real-time OGEN stock news. You can receive the latest news about Oragenics through multiple platforms. This information may help you make smarter investment decisions.
About OGEN
Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including coronaviruses and multidrug-resistant organisms. The Company's lead product, NT-CoV2-1, is an intranasal immunization vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. Its other product candidates include Terra CoV-2 and Antibiotics. Terra CoV-2 is an intramuscular vaccine candidate (plasmid + adjuvant) to provide long-lasting immunity against SARS-CoV-2. Antibiotics is a semi-synthetic analogs of MU1140, which is a member of lantibiotic class of antibiotics. The Company, through its wholly owned subsidiary, Noachis Terra, Inc. (Noachis Terra), is engaged in the research and development of its Terra CoV-2 and NT-CoV2-1 vaccine product candidates. It is also developing semi-synthetic lantibiotic analogs that may be effective against systemic Gram-positive multidrug infections, and analogs that may be effective in treating Gram negative infections.